Palestra – Dr. Frederic Zecri
Título: “From Ancient Medicine to the First Oral Treatment of Multiple Sclerosis: The Discovery of FTY720 (Gilenya™).”
. Dr. Frederic Zecri Group leader at Novartis Institutes for BioMedical Research, Inc. Data: 26 de outubro. 17 h. . |
|
Currículo resumido:.Group Leader – Novartis June 2011 – Present (1 year 5 months) Cambridge, MA, USA
Senior Research Investigator – Novartis November 2009 – June 2011 (1 year 8 months) Research Investigator – Novartis April 2002 – November 2009 (7 years 8 months) Postdoctoral Fellow – The Sripps Research Institut September 2000 – March 2002 (1 year 7 months) First total synthesis and biological evaluation of an antibiotic – Thiostrepton – and its analogs. The structure of Thiostrepton is characterized by an assembly of numerous non naturel amino acids, including dehydro-aminoacids, thiazoles, thiazoline, dehydro-piperidine and quinoline moiety. Pre-PhD intern – Rhone-Poulenc Rorer August 1998 – January 1999 (6 months) I worked on developing methodologies (scavengers, parallel purification …) for the solution phase synthesis of libraries of compounds towards potential herbicide application. Education: Imperial College London – PhD, Organic Synthesis – 1998-2000 |
Divulgação |